The Experts below are selected from a list of 2529 Experts worldwide ranked by ideXlab platform
M Geraint - One of the best experts on this subject based on the ideXlab platform.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
A randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate + Magnesium Citrate solution for bowel cleansing prior to colonoscopy.
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, Roger W. Chapman, M Thyssen, G Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
J Worthington - One of the best experts on this subject based on the ideXlab platform.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
A randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate + Magnesium Citrate solution for bowel cleansing prior to colonoscopy.
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, Roger W. Chapman, M Thyssen, G Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
Charles Y.c. Pak - One of the best experts on this subject based on the ideXlab platform.
-
Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium Magnesium Citrate: a feasibility study
Journal of Nephrology, 2019Co-Authors: Henry Quiñones, Khashayar Sakhaee, Orson W. Moe, Tamim Hamdi, Andreas Pasch, Charles Y.c. PakAbstract:Aims Cardiovascular (CV) complications are common in chronic kidney disease (CKD). Numerous metabolic disturbances including hyperphosphatemia, high circulating calciprotein particles (CPP), hyperparathyroidism, metabolic acidosis, and Magnesium deficiency are associated with, and likely pathogenic for CV complications in CKD. The goal of this feasibility study was to determine whether effervescent calcium Magnesium Citrate (EffCaMgCit) ameliorates the aforementioned pathogenic intermediates. Methods Nine patients with Stage 3 and nine patients with Stage 5D CKD underwent a randomized crossover study, where they took EffCaMgCit three times daily for 7 days in one phase, and a conventional phosphorus binder calcium acetate (CaAc) three times daily for 7 days in the other phase. Two-hour postprandial blood samples were obtained on the day before and on the 7th day of treatment. Results In Stage 5D CKD, EffCaMgCit significantly increased T50 (half time for conversion of primary to secondary CPP) from baseline by 63% ( P = 0.013), coincident with statistically non-significant declines in serum phosphorus by 25% and in saturation of octacalcium phosphate by 35%; CaAc did not change T50. In Stage 3 CKD, neither EffCaMgCit nor CaAc altered T50. With EffCaMgCit, a significant increase in plasma Citrate was accompanied by statistically non-significant increase in serum Mg and phosphate. CaAc was without effect in any of these parameters in Stage 3 CKD. In both Stages 3 and 5D, both drugs significantly reduced serum parathyroid hormone. Only EffCaMgCit significantly increased serum bicarbonate by 3 mM ( P = 0.015) in Stage 5D. Conclusions In Stage 5D, EffCaMgCit inhibited formation of CPP, suppressed PTH, and conferred Magnesium and alkali loads. These effects were unique, since they were not observed with CaAc. In Stage 3 CKD, neither of the regimens have any effect. These metabolic changes suggest that EffCaMgCit might be useful in protecting against cardiovascular complications of CKD by ameliorating pathobiologic intermediates.
-
Effects of Potassium Magnesium Citrate Supplementation on 24-Hour Ambulatory Blood Pressure and Oxidative Stress Marker in Prehypertensive and Hypertensive Subjects
American Journal of Cardiology, 2016Co-Authors: Wanpen Vongpatanasin, Poghni Peri-okonny, Alejandro Velasco, Debbie Arbique, Zhongyun Wang, Priya Ravikumar, Beverly Adams-huet, Orson W. Moe, Charles Y.c. PakAbstract:Diet rich in fruits, vegetables, and dairy products, known as the Dietary Approaches to Stop Hypertension (DASH) diet, is known to reduce blood pressure (BP) in hypertensive patients. More recently, the DASH diet was shown to reduce oxidative stress in hypertensive and nonhypertensive humans. However, the main nutritional components responsible for these beneficial effects of the DASH diet remain unknown. Because the DASH diet is rich in potassium (K), Magnesium (Mg), and alkali, we performed a randomized, double-blinded, placebo-controlled study to compare effects of potassium Magnesium Citrate (KMgCit), potassium chloride (KCl), and potassium Citrate (KCit) to allow dissociation of the three components of K, Mg, and Citrate on 24-hour ambulatory BP and urinary 8-isoprostane in hypertensive and prehypertensive subjects, using a randomized crossover design. We found that KCl supplementation for 4 weeks induced a significant reduction in nighttime SBP compared with placebo (116 ± 12 vs 121 ± 15 mm Hg, respectively, p 0.1 vs placebo). In contrast, urinary 8-isoprostane was significantly reduced with KMgCit powder compared with placebo (13.5 ± 5.7 vs 21.1 ± 10.5 ng/mgCr, respectively, p 0.1 vs placebo). In conclusion, our study demonstrated differential effects of KCl and KMgCit supplementation on BP and the oxidative stress marker in prehypertensive and hypertensive subjects. Clinical significance of the antioxidative effect of KMgCit remains to be determined in future studies.
-
Physicochemical action of potassium-Magnesium Citrate in nephrolithiasis
Journal of Bone and Mineral Research, 2009Co-Authors: Charles Y.c. Pak, Karl Koenig, Rubina Khan, Sharon Haynes, Paulette PadalinoAbstract:Effect of potassium-Magnesium Citrate on urinary biochemistry and crystallization of stone-forming salts was compared with that of potassium Citrate at same dose of potassium in five normal subjects and five patients with calcium nephrolithiasis. Compared to the placebo phase, urinary pH rose significantly from 6.06 ± 0.27 to 6.48 ± 0.36 (mean ± SD, p < 0.0167) during treatment with potassium Citrate (50 mEq/day for 7 days) and to 6.68 ± 0.31 during therapy with potassium-Magnesium Citrate (containing 49 mEq K, 24.5 mEq Mg, and 73.5 mEq Citrate per day). Urinary pH was significantly higher during potassium-Magnesium Citrate than during potassium Citrate therapy. Thus, the amount of undissociated uric acid declined from 118 ± 61 mg/day during the placebo plase to 68 ± 54 mg/day during potassium Citrate treatment and, more prominently, to 41 ± 46 mg/day during potassium-Magnesium Citrate therapy. Urinary Magnesium rose significantly from 102 ± 25 to 146 ± 37 mg/day during potassium-Magnesium Citrate therapy but not during potassium Citrate therapy. Urinary Citrate rose more prominently during potassium-Magnesium Citrate therapy (to 1027 ± 478 mg/day from 638 ± 252 mg/day) than during potassium Citrate treatment (to 932 ± 297 mg/day). Consequently, urinary saturation (activity product) of calcium oxalate declined significantly (from 1.49 × 10−8 to 1.03 × 10−8 M2) during potassium-Magnesium Citrate therapy and marginally (to 1.14 × 10−8 M2) during potassium Citrate therapy. Moreover, the formation product of calcium phosphate (brushite), indicative of inhibition against spontaneous nucleation, rose more prominently during potassium-Magnesium Citrate treatment (from 4.62 × 10−7 to 8.78 × 10−7 M2) than during potassium Citrate therapy (to 6.08 × 10−7 M2). The inhibition against agglomeration of calcium oxalate increased marginally (p = 0.02) during potassium-Magnesium Citrate therapy, whereas it did not change significantly during potassium Citrate treatment. Thus, potassium-Magnesium Citrate (at same dose of potassium) is more effective than potassium Citrate in inhibiting the crystallization of uric acid and calcium oxalate in urine.
-
Reduction of Renal Stone Risk by Potassium-Magnesium Citrate During 5 Weeks of Bed Rest
The Journal of Urology, 2007Co-Authors: Joseph E. Zerwekh, Lisa Ann Wuermser, Clarita V. Odvina, Charles Y.c. PakAbstract:Purpose: Exposure to the microgravity environment of space increases the risk of kidney stone formation, particularly for calcium oxalate and uric acid stones. This study was performed to evaluate the efficacy of potassium alkali as potassium-Magnesium Citrate in reducing renal stone risk and bone turnover.Materials and Methods: This study was performed as a double-blind, placebo controlled trial. We studied 20 normocalciuric subjects randomized to either placebo or potassium-Magnesium Citrate (42 mEq potassium, 21 mEq Magnesium, 63 mEq Citrate per day) before and during 5 weeks of strict bed rest. The study was performed in the General Clinical Research Center and under a controlled dietary regimen composed of 100 mEq of sodium, 800 mg of calcium, 0.8 gm/kg animal protein and 2,200 kcal per day. Two 24-hour urine collections were obtained under oil each week for assessment of stone risk parameters and relative saturation of calcium oxalate, brushite and undissociated uric acid. Blood was also collected f...
-
Prevention of thiazide-induced hypokalemia without Magnesium depletion by potassium-Magnesium-Citrate.
American Journal of Therapeutics, 2006Co-Authors: Clarita V. Odvina, Ralph P. Mason, Charles Y.c. PakAbstract:Thiazide can cause Magnesium depletion, which may exaggerate renal potassium wasting and hypokalemia. The purpose of this double-blind, randomized trial was to compare the metabolic effects of potassium-Magnesium-Citrate (K-Mg-Citrate) and potassium chloride (KCl) during long-term treatment with thiazide. Twenty-two normal volunteers received hydrochlorothiazide 50 mg/d. Ten subjects concurrently took K-Mg-Citrate (42 mEq K/d and 21 mEq Mg/d), and 12 subjects were given KCl 42 mEq/d. Serum potassium concentration remained unchanged during K-Mg-Citrate supplementation, with a change from baseline of 21.7% over 6 months, compared with 26.4% with KCl supplementation. Serum electrolytes were normal and not significantly different between K-Mg-Citrate and KCl. During K-Mg-Citrate treatment, serum Magnesium increased significantly by about 10%, associated with an adequate increase in urinary Magnesium and a nonsignificant increase in monocyte and free muscle Magnesium. Serum Magnesium was unchanged, and monocyte and free muscle Magnesium showed a nonsignificant decline during KCl supplementation. K-Mg-Citrate provided an alkali load, increasing urinary pH, and reducing urinary undissociated uric acid. It also increased urinary Citrate and tended to lower the saturation of calcium oxalate. KCl supplementation lacked these actions. K-Mg-Citrate prevents thiazide-induced hypokalemia without provoking metabolic alkalosis. It seems to prevent Magnesium depletion. By providing an alkali load, it retards the propensity for the crystallization of uric acid and probably of calcium oxalate. Though not conclusive, KCl supplementation may be less effective than K-Mg-Citrate in maintaining normokalemia because of a subtle Magnesium wasting. Moreover, KCl is devoid of protective action toward crystallization of stone-forming salts.
M Thyssen - One of the best experts on this subject based on the ideXlab platform.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
A randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate + Magnesium Citrate solution for bowel cleansing prior to colonoscopy.
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, Roger W. Chapman, M Thyssen, G Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
G Chapman - One of the best experts on this subject based on the ideXlab platform.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
A randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate + Magnesium Citrate solution for bowel cleansing prior to colonoscopy.
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, Roger W. Chapman, M Thyssen, G Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
-
a randomised controlled trial of a new 2 litre polyethylene glycol solution versus sodium picosulphate Magnesium Citrate solution for bowel cleansing prior to colonoscopy
Current Medical Research and Opinion, 2008Co-Authors: J Worthington, M Thyssen, G Chapman, R W Chapman, M GeraintAbstract:BACKGROUND: A new 2 L polyethylene glycol (PEG) solution containing ascorbic acid (Asc) and electrolytes (Moviprep) has been developed for bowel cleansing. OBJECTIVES: To compare the efficacy, safety and acceptability of PEG + Asc versus sodium picosulphate + Magnesium Citrate in patients scheduled to undergo colonoscopy. DESIGN AND METHODS: This single blind, parallel group pilot study included 65 adult male and female patients. A blinded assessment of cleansing was made for each bowel segment by the colonoscopist and the scores determined an overall grading of bowel cleansing. Patients completed a questionnaire on the acceptability of the preparation. RESULTS: Successful bowel preparation was reported in 84.4% of patients who received PEG + Asc and 72.7% of patients who received sodium picosulphate + Magnesium Citrate (treatment difference +11.6, 95% CI -11.2, +34.5; p = 0.367). Patients were more likely to have a higher overall quality of bowel cleansing with PEG + Asc (p = 0.018), with specifically better cleansing in the ascending colon (p = 0.024) and caecum (p = 0.003) compared with patients who received sodium picosulphate + Magnesium Citrate. The adverse event profile of the two treatments was similar, with headache and gastrointestinal effects being the most commonly reported. Some patient acceptability results favoured sodium picosulphate + Magnesium Citrate for those patients who had experience of previous bowel preparation, but were similar for those patients who had not had a previous bowel preparation. CONCLUSIONS: PEG + Asc provided effective bowel cleansing, which was equivalent to that of sodium picosulphate + Magnesium Citrate in terms of grading cleansing as overall success or failure. In the proximal colon (ascending colon and caecum) PEG + Asc provided significantly better cleansing to that achieved with sodium picosulphate + Magnesium Citrate.
